Anemia in patients on combined androgen block therapy for prostate cancer / 亚洲男科学杂志(英文版)
Asian Journal of Andrology
; (6): 383-384, 2004.
Article
in En
| WPRIM
| ID: wpr-270880
Responsible library:
WPRO
ABSTRACT
<p><b>AIM</b>To study the effect of combined androgen block therapy on hemoglobin and hematocrit values in patients with prostate cancer.</p><p><b>METHODS</b>One hundred and thirty-six patients with adenocarcinoma of prostate were treated with combined androgen block (orchiectomy and flutamide 250 mg, tid). Complete blood counts were determined before and after 1, 2, 3, 6, 9 and 12 months of therapy.</p><p><b>RESULTS</b>The hemoglobin and hematocrit levels declined significantly in all patients and at all the time points after treatment (P<0.05).</p><p><b>CONCLUSION</b>Prostate cancer patients treated with combined androgen block would develop obvious anemia. Recombinant human erythropoietin can be used to treat patients with severe anemia.</p>
Full text:
1
Database:
WPRIM
Main subject:
Prostatic Neoplasms
/
Therapeutics
/
Hemoglobins
/
Orchiectomy
/
Adenocarcinoma
/
Combined Modality Therapy
/
Antineoplastic Agents, Hormonal
/
Prostatic Secretory Proteins
/
Therapeutic Uses
/
Drug Therapy
Limits:
Adult
/
Humans
/
Male
Language:
En
Journal:
Asian Journal of Andrology
Year:
2004
Document type:
Article